Archive · 29 Sep 2026
Natco Pharma Raises eGenesis Investment to $16.70 Million
Natco Pharma is putting more money into a biotechnology company called eGenesis.
The planned investment is increasing from $14 million to $16.70 million.
Two Natco subsidiaries will provide the money.
Most of it will come from NATCO Pharma (Canada) Inc.
The rest will come from NATCO Pharma USA LLC.
The money will buy notes that earn 8% interest compounded each year.
Natco does not plan to receive additional shares when the deal is completed.
The deal is expected to finish by October 31 and is meant to support treatments for important medical needs.
Natco Pharma will increase its planned investment in eGenesis to $16.70 million from $14 million.
NATCO Pharma (Canada) Inc will invest $13.70 million, while NATCO Pharma USA LLC will contribute $3 million.
The investment will purchase 8% convertible promissory notes through a cash transaction.
Completion is expected by October 31, with no additional shares acquired at closing.
Natco had invested $8 million in eGenesis in 2024, bringing its total planned investment to $24.70 million.
- Who
- Natco Pharma Ltd, through NATCO Pharma (Canada) Inc and NATCO Pharma USA LLC, and US-based biotechnology firm eGenesis Inc.
- What
- Natco Pharma is raising its proposed eGenesis investment to $16.70 million by purchasing convertible promissory notes.
- When
- The announcement was made on September 29, 2026; completion is expected by October 31.
- Where
- eGenesis is based in the United States.
- Why
- Natco said the investment will support new-age therapeutic programs addressing critical unmet medical needs.
- Revised investment
- $16.70 million, approximately Rs 139 crore
- Previously disclosed amount
- $14 million
- NATCO Pharma (Canada) Inc contribution
- $13.70 million
- NATCO Pharma USA LLC contribution
- $3 million
- Investment instrument
- Convertible promissory notes purchased for cash
- Interest rate
- 8% compounded annually
- Total Natco investment after completion
- $24.70 million